NeoImmuneTech, Inc. (KOSDAQ:950220)

South Korea flag South Korea · Delayed Price · Currency is KRW
555.00
-32.00 (-5.45%)
At close: Feb 27, 2026
Market Cap54.87B -50.8%
Revenue (ttm)94.29M -28.6%
Net Income-29.66B
EPS-92.75
Shares Out98.87M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume1,716,060
Average Volume2,135,476
Open586.00
Previous Close587.00
Day's Range542.00 - 586.00
52-Week Range516.00 - 1,881.00
Beta0.50
RSI35.14
Earnings DateMar 20, 2026

About NeoImmuneTech

NeoImmuneTech, Inc., a clinical-stage T cell-based biotechnology company, develops and sells immuno-therapeutics in Korea. It is developing NT-I7, a clinical-stage more stable in the body, providing prolonged T cell amplification effects IL-7 for oncologic and infectious diseases; and Heterodimer hybrid Fc platform, an antibody platform technology, as well as NT2020, a T cell activator; NT3020, a T cell engager; NT4010, an advanced CAR-T; and NT5010, a TME modifier. The company was incorporated in 2014 and is headquartered in Rockville, Marylan... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2014
Employees 52
Stock Exchange KOSDAQ
Ticker Symbol 950220
Full Company Profile

Financial Performance

Financial Statements